格隆汇3月24日丨友芝友生物-B(02496.HK)公告,集团预计截至2024年12月31日止年度将录得的综合亏损将较截至2023年12月31日止年度的综合亏损人民币191.7百万元减少至少35%。董事会认为,上述综合亏损的减少主要归因于(i)公司与正大天晴药业集团股份有限公司于2024年10月7日订立的许可与合作协议项下的交易;及(ii)于2023年录得上市开支约人民币24.6百万元(2024年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.